Exchange: NASDAQ·Updated 04:00 PM EDT
NKTX logo

NKTXNkarta Inc

$2.58
$0.01
(0.39%)
Today
EarningsAug 12
Mkt Cap$183.87M
Vol473,725.00
News
all
press releases
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...
PR Newswire
More News
The $13 Million Company Teaching the Immune System to Hunt Cancer
The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...
PR Newswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...
PR Newswire
Nkarta (NKTX) Projected to Post Earnings on Wednesday
Nkarta (NASDAQ:NKTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts
Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) has been given a consensus rating of "Hold" by the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has...
MarketBeat
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1% - Here's Why
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1% - Here's Why...
MarketBeat
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
Zacks
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Hold" by Analysts
Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to...
MarketBeat
Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho
Mizuho dropped their price target on shares of Nkarta from $14.00 to $12.00 and set an "outperform" rating on the stock in a research report on Tuesday...
MarketBeat
HC Wainwright Forecasts Nkarta's Q1 Earnings (NASDAQ:NKTX)
Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Analysts at HC Wainwright cut their Q1 2026 earnings estimates for Nkarta in a research report issued to clients and investors on Thursday, March 26th. HC...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.